source
- Chinese biotech CEOs say US tensions won’t curb booming licensing dealsChinese biotech CEOs say they are not worried about rising US political tension and regulatory scrutiny. US lawmakers have increased scrutiny, referencing the America First Investment Policy and t…
- Amylyx's avexitide halves hypoglycemia episodes in phase 3 trial for post‑bariatric patientsAmylyx Pharmaceuticals reported that its GLP‑1 receptor antagonist avexitide significantly reduced dangerous blood‑sugar drops in a phase 3 study. The double‑blind Lucidity trial enrolled 78 indiv…